Company intelligence / Profile preview

CALICOTE

South San Francisco, California, United Statescalicote.com ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Calico has an expanding pipeline of early-stage and clinical-stage compounds targeting diseases linked with aging. Its most publicized program is a PTPN2 inhibitor in phase 1 studies for immuno-oncology. The company also has a candidate called fosigotifator (ABBV-CLS-7262) selected by the FDA START Pilot Program for vanishing white matter disease. Most other programs remain undisclosed or are at preclinical stages.

Therapeutic areas: OncologyNeurologyOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

AbbVie ($3B+ R&D collaboration focused on age-related diseases including cancer & neurodegeneration)Terray Therapeutics (small-molecule R&D partnership)various academic collaborations including UCSF and others.

Beyond the preview

Go deeper on CALICOTE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CALICOTE.

Explore the full profile